H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Rockwell Medical (RMTI) to $7 from $9 and keeps a Buy rating on the shares post the Q3 report. The company’s largest customer made a special premium products order, but expects future volumes to decline due to supplier diversification, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMTI: